Axsome Therapeutics (AXSM) Inventory Average (2022 - 2026)

Axsome Therapeutics has disclosed Inventory Average across 5 years of filings, most recently posting $29.7 million for Q1 2026.

• Inventory Average for Q1 2026 came in at $29.7 million, up 85.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.7 million (up 85.49% YoY), and the FY2025 annual result was $21.8 million, up 41.48% from the prior year.
• Inventory Average came in at $29.7 million for Q1 2026 at Axsome Therapeutics, up from $25.9 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $29.7 million in Q1 2026 to a low of $6.1 million in Q1 2023.
• The 5-year median for Inventory Average is $15.0 million (2024), against an average of $15.3 million.
• Across the five-year window, Inventory Average decreased 20.87% in 2023 and jumped 150.55% in 2024, its largest moves.
• Axsome Therapeutics' Inventory Average stood at $9.2 million in 2022, then surged by 37.21% to $12.6 million in 2023, then grew by 19.41% to $15.0 million in 2024, then soared by 72.39% to $25.9 million in 2025, then gained by 14.97% to $29.7 million in 2026.
• The last three Inventory Average figures came in at $29.7 million (Q1 2026), $25.9 million (Q4 2025), and $21.1 million (Q3 2025), per Business Quant data.